Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.
To evaluate the survival benefit of adding vaginal brachytherapy (BT) to pelvic external beam radiation therapy (EBRT) in women with stage III endometrial cancer.



The National Cancer Data Base was used to identify patients with stage III endometrial cancer from 2004 to 2013. Only women who received adjuvant EBRT were analyzed. Women were grouped according to receipt of BT. Logistic regression modeling was used to identify predictors of receiving BT. Log-rank statistics were used to compare survival outcomes. Cox proportional hazards modeling was used to evaluate the effect of BT on survival. A propensity score-matched analysis was also conducted among women with cervical involvement.



We evaluated 12,988 patients with stage III endometrial carcinoma, 39% of whom received EBRT plus BT. Women who received BT were more likely to have endocervical or cervical stromal involvement (odds ratios 2.03 and 1.77; P<.01, respectively). For patients receiving EBRT alone, the 5-year survival was 66% versus 69% with the addition of BT at 5 years (P<.01). Brachytherapy remained significantly predictive of decreased risk of death (hazard ratio 0.86; P<.01) on multivariate Cox regression. The addition of BT to EBRT did not affect survival among women without cervical involvement (P=.84). For women with endocervical or cervical stromal invasion, the addition of BT significantly improved survival (log-rank P<.01). Receipt of EBRT plus BT was associated with improved survival in women with positive and negative surgical margins, and receiving chemotherapy did not alter the benefit of BT. Propensity score-matched analysis results confirmed the benefit of BT among women with cervical involvement (hazard ratio 0.80; P=.01).



In this population of women with stage III endometrial cancer the addition of BT to EBRT was associated with an improvement in survival for women with endocervical or cervical stromal invasion.
Department of Radiation Oncology, Vanderbilt University, Nashville, Tennessee.
Brian
B
Bingham
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah.
Andrew
A
Orton
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah.
Dustin
D
Boothe
Division of Epidemiology, University of Utah, Salt Lake City, Utah.
Greg
G
Stoddard
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah.
Y Jessica
YJ
Huang
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah.
David K
DK
Gaffney
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah. Electronic address: Matthew.poppe@hci.utah.edu.
Matthew M
MM
Poppe
D000368:Aged; D001918:Brachytherapy / Q000401:mortality* / Q000706:statistics & numerical data; D003131:Combined Modality Therapy / Q000401:mortality / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D015995:Prevalence; D020266:Radiotherapy, Conformal / Q000401:mortality* / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*